We welcome your feedback! For more information, questions, suggestions for the website, or if you are interested in precepting students, contact us at 


You may also reach out to us below:


281 E Colorado Blvd
PO Box 1145
Pasadena, CA 91102




January 2020 Newsletter »
July 2019 Newsletter »

January 2019 Newsletter »



March 9, 2020: 

FDA draft guidance eliminates CV outcomes trial recommendation for diabetes drug approvals

February 15, 2020: 

FDA recall on Medtronic pumps - 600 series

February 13, 2020:

FDA voluntary recall of anti-obesity drug Belviq

January 28, 2020:

FDA okays triple-combo pill for type 2 diabetes

January 16, 2020:

FDA Approves Semaglutide Injection for Cardiovascular Risk Reduction

January 6, 2020:

Fiasp is now approved for children with diabetes


December 13, 2019:

FDA approves Tandem Diabetes Care Control IQ Technology, a integrated insulin pump + continuous glucose sensor


October 22, 2019: 
FDA OKs Faster-Acting Insulin Aspart for Pump Use (Fiasp)


October 21, 2019: 
FDA OKs Dapagliflozin to Reduce HF Hospitalization in Diabetes (Farxiga)


September 30, 2019: 
FDA OKs Canagliflozin to Curtail Diabetic Kidney Disease (Invokana)


September 20, 2019:
FDA OKs 'Game-Changer' Oral GLP-1 Agonist for Type 2 Diabetes (Rybelsus)


September 12, 2019:
FDA Approves New Glucagon Pen to Treat Hypoglycemia

Bulletin from The Endocrine Society: NATPARA Recall


CMHC’s Monthly Newsletter:



ASEPA members meet twice a year at the following conferences: AAPA and AACE. We also meet informally at the MEDS East and MEDS West conferences.


Throughout the year, board members communicate frequently via email and conference calls.